Scopio is changing the standard of healthcare and revolutionizing first-line diagnostic testing by harnessing the power of computational photography and AI to image and analyze the morphology of cells at a scale that was never possible before, expediting access to life-saving treatments and improved patient outcomes.
Scopio Labs was founded by two physicists and visionaries determined to push the boundaries of medicine and innovate in a way that would do some good in the world.
Early in their careers, Itai Hayut and Erez Na’aman dreamed of a collaboration. After witnessing medical practitioners in the hematology lab who still rely on analog, outdated, and labor-intensive practices using traditional microscopes and manual cell counts, they realized that with their backgrounds in physics, IT and medical device technology and the evolution of deep learning, they could use AI-powered analysis to bring microscopy and hematology into the digital age. All they needed was to find a scanner to digitize the slides, and the rest would fall into place.
But no such scanner existed, and so that’s where the Scopio story began.
The result is a series of innovations that brings high-quality data and advancements in deep learning to the practice of hematology, transforming the future of disease detection and diagnosis forever.
Co-Founder and CEO
Co-Founder and CTO
Eran Small PhD
Amy Meitus MD
Chief Product Officer
Ben Leshem PhD
VP Imaging & Research
VP Global Hematology Sales
Meet the Scopio Team
Shaked Ben Baruch
Mira Shem Tov
June 9, 2022: Scopio Labs Awarded FDA Clearance for High Throughput Hematology Digital Cell Morphology Platform, Replacing Microscopes with Digitization. This is the company’s second FDA clearance, broadening its suite of fully digital platforms to cater to all lab sizes and networks
Feb 9, 2022: Scopio raises $50M to take a deeper look into our blood cells. The company’s ultra high quality and FDA-cleared imaging and AI analysis platforms enhance diagnostic capabilities and enable remote work
Sept 27, 2021: Scopio Labs Launches Full-Field Peripheral Blood Smear Application, Bringing End-to-End Digital Workflow to Hematology Labs to Transform Diagnostic Testing
Oct 21, 2020: FDA Clearance of Full Field PBS Application. The First Ever Solution to Enable Digitization and Analysis of Full Field Peripheral Blood Smears with Decision Support System (DSS) Tailored to Augment Hematology Diagnostics
Apr. 28, 2020: Scopio Labs Closes $16 Million Series B Round to Expand Commercial Rollout of Automated Microscopy Solutions. All-Digital AI-Powered Platform to Reduce Human Error, Connect Remote Experts, Increase Diagnostic Lab Reliability and Efficiency
Apr. 13, 2020: Scopio Labs Receives CE Mark for X100 Microscope and Decision Support System With Full Field Peripheral Blood Smear (PBS) Application. All-Digital Automated Scanning and AI-Powered Analysis Enables Precise and Comprehensive Diagnosis, Remote Consultation and Accelerated Results to Improve Care Outcomes
Notable Media Coverage
Clinical Lab Products (CLP): High Throughput Hematological Analysis Platform Receives FDA Clearance
EXBULLETIN: Scopio Labs obtains FDA approval for blood smear
Jerusalem Post: Hillel’s Tech Corner: AI meets telescopy at Scopio Labs
Fortune Term Sheet: The venture capitalist at the center of the coronavirus fight
CTech by Calcalist: Digital Microscope Startup Scopio Labs Raises $16 Million